Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.42 |
| ▸ | PSEN1 | P49768 | 5/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6499586 | 0.87 | PSEN1 (0.44) | UHRF1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5899050 | 0.84 | NOS3 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3660321 | 0.83 | PSEN1 (0.40) | UHRF1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6499767 | 0.81 | CYP3A4 (0.35) | — | |
| SCHEMBL7394777 | 0.81 | PTGDR2 (0.38) | UHRF1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6502000 | 0.80 | NOS3 (0.34) | — | |
| SCHEMBL27924262 | 0.75 | UHRF1 (0.43) | UHRF1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6503969 | 0.74 | GABRA5 (0.39) | — | |
| SCHEMBL4061188 | 0.74 | UHRF1 (0.42) | UHRF1PSEN1PSEN2APH1BNCSTN | |
| Bromide SCHEMBL14676184 | 0.72 | UHRF1 (0.41) | UHRF1PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080113-A1 | Medicinal compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080113-A1 | Medicinal compositions | TNF, TRAF6, MMP8 | UHRF1 4269/4885PSEN1 3987/4885PSEN2 4121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.